Perspective Therapeutics’ (CATX) “Buy” Rating Reaffirmed at HC Wainwright

Perspective Therapeutics (NYSE:CATX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 354.55% from the company’s current price.

Several other equities analysts also recently issued reports on CATX. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Scotiabank started coverage on Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.20 on Monday. The firm has a 50-day moving average price of $2.94 and a 200 day moving average price of $6.29. Perspective Therapeutics has a twelve month low of $2.18 and a twelve month high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Perspective Therapeutics by 19.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after acquiring an additional 11,472 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth about $1,595,000. Squarepoint Ops LLC acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $626,000. Wexford Capital LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $64,000. Finally, Two Sigma Advisers LP acquired a new position in Perspective Therapeutics during the 4th quarter worth approximately $484,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.